Evidence map›Paper›PMID 40136396›Full record

ArticleCurrent issues in molecular biology2025

Biological Disease-Modifying Antirheumatic Drugs Decrease Uric Acid Levels in the Sera of Patients with Psoriatic Arthritis.

Dijana Perković, Marin Petrić, Maja Maleš, Ivana Erceg Maleš, Mislav Radić

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current issues in molecular biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Dijana PerkovićDivision of Clinical Immunology and Rheumatology, Department of Internal Medicine, University Hospital of Split, 21000 Split, Croatia.
Marin PetrićDivision of Clinical Immunology and Rheumatology, Department of Internal Medicine, University Hospital of Split, 21000 Split, Croatia.ORCID 0000-0002-5282-9633
Maja MalešDepartment of Internal Medicine, School of Medicine, University of Split, 21000 Split, Croatia.
Ivana Erceg MalešDivision of Clinical Immunology and Rheumatology, Department of Internal Medicine, University Hospital of Split, 21000 Split, Croatia.
Mislav RadićDivision of Clinical Immunology and Rheumatology, Department of Internal Medicine, University Hospital of Split, 21000 Split, Croatia.ORCID 0000-0003-0350-6800

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThere are many explanations for increased levels of serum uric acid (SUA) in patients with psoriatic arthritis (PsA), but correlation with different treatment options in PsA is not well elucidated. Our aim was to determine the effects of biological disease-modifying antirheumatic drugs (bDMARDs) on SUA levels in patients with PsA. MATERIALS AND

methodsWe analyzed the data of PsA patients treated with different bDMARDs from January 2007 to June 2021. Patients treated with interleukin-17 (IL-17) inhibitors (secukinumab and ixekizumab) and tumor necrosis factor α (TNFα) inhibitors (golimumab, infliximab, adalimumab, certolizumab pegol, and etanercept) were included.

resultsA total of 87 patients were included. The SUA levels decreased in 60 (69%) patients after a 3-6-month-long follow-up, and in 25 (28.7%), we noticed an increase. The average decrease in SUA levels was 9.4 ± 49.5 µmol/L (

conclusionsA significant decrease in SUA levels was noticed, especially in patients treated with IL-17 inhibitors. Further studies should identify which bDMARD is the most potent in the lowering of SUA levels. bDMARDs were efficient in PsA disease activity.

Indexed as

biological disease-modifying antirheumatic drugsinterleukin-17psoriatic arthritistumor necrosis factor alphauric acid

Identifiers

PMID40136396
PMCPMC11941369

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.